COMP <GO>
OMER vs LBRX // GROSS PROFIT MARGIN
Omeros Corporation (NASDAQ) VS. LB Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: OMER 1
— LBRX 4
■ METRIC PARITY
LAST: $18.27 (+2.47%) • MKT CAP: $1.29B
gross-margins
—
LAST: $40.33 (+3.30%) • MKT CAP: $1.26B
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMER VS. LBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OMER | LBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -8.40% | -26.60 | LBRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.47% | -2.72% | -5.75 | LBRX | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | LBRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.9 | 49.6 | -0.70 | LBRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $1.26B | $31.3M | OMER | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OMER REV | LBRX REV | OMER GROSS % | LBRX GROSS % | OMER FCF | LBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $343.8M | $131.4M | — | — | -$116.2M | -$35.3M |
| FY 2024 | $467.5M | $14.1M | — | — | -$149.0M | -$53.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMER // BETA —
LBRX // BETA —